CPT code 88165 denotes a manual cytopathology procedure in which a laboratory analyst performs the technical examination of a cervical or vaginal cytology slide and then manually rescreens the same slide under physician supervision, using the Bethesda System for reporting. This code captures an important quality-control workflow step in cervical cancer screening and diagnostic cytology, reflecting labor-intensive manual review that can affect laboratory throughput, reporting accuracy, and payment determinations. Nationally, manual cytology and rescreening remain relevant for facilities that do not use primary automation or adjunctive molecular testing, and for cases requiring expert manual review.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context and service settings, typical billing considerations, and payer coverage outlines. The publication also provides benchmarks where available, notes on policy and coding updates that affect cytology services, and practical context for laboratory administrators and billing professionals.

The content emphasizes clinical and coding clarity — how the service is defined, where it is typically performed, and which payers commonly cover it. Data not provided in the input (such as specific reimbursement rates, associated taxonomies, or ICD-10 pairings) are noted as unavailable and are not fabricated here.